Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T17:07:59.966Z.
Calculation as of: 2026-10-06T17:07:59.966Z.
Quote observation: 2026-10-06T17:05:21.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 69a1d57d3f318828ebe19021960b74268097702d5d6050a421f3255bba496414
PEG RATIO
N/A
Market Cap
$948.56M
PEG Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$977.59M
PEG Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PEG RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| MoonLake Immunotherapeutics (MLTX) | $936.20M | N/A | N/A | N/A | N/A |
| CeriBell, Inc. (CBLL)vs › | $930.73M | N/A | N/A | N/A | N/A |
| Seaport Therapeutics, Inc. Common Stock (SPTX)vs › | $948.56M | N/A | N/A | N/A | N/A |
| Kura Oncology, Inc. (KURA)vs › | $949.44M | N/A | N/A | N/A | N/A |
| Savara Inc. (SVRA)vs › | $953.94M | N/A | N/A | N/A | N/A |
| Odyssey Therapeutics, Inc. (ODTX)vs › | $913.56M | N/A | N/A | N/A | N/A |
| HealthStream, Inc. (HSTM)vs › | $914.89M | 6.49 | 5.08 | 6.65 | 9.17 |
| Aktis Oncology, Inc. (AKTS)vs › | $968.36M | N/A | N/A | N/A | N/A |
| LB Pharmaceuticals Inc Common Stock (LBRX)vs › | $977.59M | N/A | N/A | N/A | N/A |
| MeiraGTx Holdings plc (MGTX)vs › | $979.81M | N/A | N/A | N/A | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
